Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: A cross-sectional study in healthy women

European Journal of Endocrinology

Volumn 150, Issue 2, 2004, Pages 161-171

  Lukanova, A ^a,b   Lundin, E ^c   Zeleniuch Jacquotte, A ^d   Muti, P ^e   Mure, A ^a,f   Rinaldi, S ^a   Dossus, L ^a   Micheli, A ^g   Arslan, A ^d   Lenner, P ^b   Shore, R E ^e   Krogh, V ^g   Koenig, K L ^e   Riboli, E ^a   Berrino, F ^g   Hallmans, G ^b   Stattin, P ^a,b   Toniolo, P ^d   Kaaks, R ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f UNIVERSITÉ DE TOULOUSE   (France)

^g NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; ESTRADIOL; ESTROGEN; ESTRONE; PEPTIDE HORMONE; PRASTERONE SULFATE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; ENDOMETRIUM CANCER; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; NONLINEAR SYSTEM; OBESITY; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AGED; ANDROGENS; ANDROSTENEDIONE; BODY MASS INDEX; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; REFERENCE VALUES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 12144287363     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500161     Document Type: Article

References (68)

1. Key TJ, Allen NE, Verkaslo PK & Banks E. Energy balance and cancer: the role of sex hormones. Proceedings of the Nutritional Society 2001 60 81-89.
2. Kaaks R & Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proceedings of the Nutritional Society 2001 60 91-106.
3. Metabolic consequences of overweight, underweight and physical activity/inactivity. In Weight Control and Physical Activity, edn 1, ch 4, pp 53-82. Eds H Vainio & F Bianchini. Lyon. France: IARC Press, 2002.
4. Endogenous Hormones and Breast Cancer Collaborative Group, Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 2002 94 606-616.
5. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. International Journal of Cancer 2004 108 262-268.
6. Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. International Journal of Cancer 2002 101 549-554.
7. Janssen JA, Stolk RP, Pols HA, Grobbee DE, de Jong FH & Lamberts SW. Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels. Clinical Endocrinology 1998 48 471-478.
8. Helle SI, Ekse D, Holly JM & Lonning PE. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. Journal of Steroid Biochemistry and Molecular Biology 2002 81 95-102.
9. Pfeilschifter J, Scheidt NC, Leidig BG, Woitge HW, Blum WF, Wuster C et al. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and women. Journal of Clinical Endocrinology and Metabolism 1996 81 2534-2540.
10. Hulten K, Winkvist A, Lenner P, Johansson R, Adlercreutz H & Hallmans G. An incident case-referent study on plasma enterolactone and breast cancer risk. European Journal of Nutrition 2002 41 168-176.
11. Sonnenschein EG, Kim MY, Pasternack BS & Toniolo PG. Sources of variability in waist and hip measurements in middle-aged women. American Journal of Epidemiology 1993 138 301-309.
12. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiology Biomarkers & Prevention 2002 11 1065-1071.
13. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C & Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiology Biomarkers & Prevention 1995 4 649-654.
14. Micheli A, Muti P, Pisani P, Secreto G, Recchione C, Totis A et al. Repeated serum and urinary androgen measurements in premenopausal and postmenopausal women. Journal of Clinical Epidemiology 1991 44 1055-1061.
15. Goodman GD & Barrett CE. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. American Journal of Epidemiology 1997 145 970-976.
16. Siiteri PK. Adipose tissue as a source of hormones. American Journal of Clinical Nutrition 1987 45 277-282.
17. Evans DJ, Hoffmann RG, Kalkhoff RK & Kissebah AH. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. Journal of Clinical Endocrinology and Metabolism 1983 57 304-310.
18. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G & Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. Journal of Clinical Endocrinology and Metabolism 1996 81 2854-2864.
19. Goodman-Gruen D & Barrett-Connor E. Total but not bioavailable testosterone is a predictor of central adiposity in postmenopausal women. International Journal of Obesity Related Metabolic Disorders 1995 19 293-298.
20. Kaye SA, Folsom AR, Soler JT, Prineas RJ & Potter JD. Associations of body mass and fat distribution with sex hormone concentrations in postmenopausal women. International Journal of Epidemiology 1991 20 151-156.
21. Newcomb PA, Klein R, Klein BE, Haffner S, Mares-Perlman J, Cruickshanks KJ et al. Association of dietary and life-style factors with sex hormones in postmenopausal women. Epidemiology 1995 6 318-321.
22. Wajchenberg BL, Marcondes JA, Mathor MB, Achando SS, Germak OA & Kirschner MA. Free testosterone levels during the menstrual cycle in obese versus normal women. Fertility and Sterility 1989 51 535-537.
23. Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G & Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. Journal ol Clinical Endocrinology and Metabolism 1990 70 473-479.
24. Sowers MF, Beebe JL, McConnell D, Randolph J & Jannausch M. Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status. American Journal of Epidemiology 2001 153 256-264.
25. Bancroft J & Cawood EH. Androgens and the menopause; a study of 40-60-year-old women. Clinical Endocrinology 1996 45 577-587.
26. Endogenous Hormones and Breast Cancer Collaborative Group. Body mass index, serum hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute (In Press).
27. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, Koenig KL, Shore RE, Kim MY et al. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. American Journal of Epidemiology 1997 145 1030-1038.
28. Bernasconi D, Del Monte P, Meozzi M, Randazzo M, Marugo A, Badaracco B et al. The impact of obesity on hormonal parameters in hirsute and nonhirsute women. Metabolism 1996 45 72-75.
29. Ivandic A, Prpic-Krizevac I, Sucic M & Juric M. Hyperinsulinemia and sex hormones in healthy premenopausal women: relative contribution of obesity, obesity type, and duration of obesity. Metabolism 1998 47 13-19.
30. Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A et al. The relation of body size to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States). Cancer Causes and Control 1995 6 3-8.
31. Madigan MP, Troisi R, Potischman N, Dorgan JF, Brinton LA & Hoover RN. Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes and Control 1998 9 199-207.
32. Poretsky L & Kalin MF. The gonadotropic function of insulin. Endocrine Reviews 1987 8 132-141.
33. Bergh C, Carlsson B, Olsson JH, Selleskog U & Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertility and Sterility 1993 59 323-331.
34. McGee EA, Sawetawan C, Bird I, Rainey WE & Carr BR. The effect of insulin and insulin-like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal-like tumor cell model. Fertility and Sterility 1996 65 87-93.
35. Corbould AM, Bawden MJ, Lavranos TC, Rodgers RJ & Judd SJ. The effect of obesity on the ratio of type 3 17beta-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. International Journal of Obesity Related Metabolic Disorders 2002 26 165-175.
36. Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK & Key TJ. Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I). C-peptide and hormone binding protein levels in British women. Cancer Causes and Control 2003 14 65-74.
37. Lukanova A, Toniolo P, Akhmedkhanov A, Hunt K, Rinaldi S, Zeleniuch-Jacquotte A et al. A cross-sectional study of IGF-I determinants in women. European Journal of Cancer Prevention 2001 10 443-452.
38. Lukanova A, Soderberg S, Stattin P, Palmqvist R, Lundin E, Biessy C et al. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes and Control 2002 13 509-516.
39. Holmes MD, Pollak MN & Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiology Biomarkers and Prevention 2002 11 862-867.
40. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S & Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes/Metabolism Research and Reviews 1999 15 314-322.
41. Grumbach MM & Styne DM. Puberty: ontogeny, neuroendocrinology, physiology, and disorders. In Williams Textbook of Endocrinology, edn 8, ch. 22, pp 1139-1221. Eds JD Wilson & DW Foster. Philadelphia, Pennsylvania: WB Saunders Company, 1998.
42. van Kesteren P, Lips P, Gooren LJ, Asscheman H & Megens J. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clinical Endocrinology 1998 48 347-354.
43. Arisaka O, Hoshi M, Kanazawa S, Nakajima D, Numata M, Nishikura K et al. Systemic effects of transdermal testosterone for the treatment of microphallus in children. Pediatrics International 2001 43 134-136.
44. Heald A, Selby PL, White A & Gibson JM. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. American Journal of Obstetrics and Gynecology 2000 183 593-600.
45. Campagnoli C, Biglia N, Peris C & Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecological Endocrinology 1995 9 67-74.
46. Ho KK, O'Sullivan AJ, Weissberger AJ & Kelly JJ. Sex steroid regulation of growth hormone secretion and action. Hormone Research 1996 45 67-73.
47. Campagnoli C, Biglia N, Altare F, Lanza MG, Lesca L, Cantamessa C et al. Differential effects of oral conjugated estrogens and transdermal extradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecological Endocrinology 1993 7 251-258.
48. O'Sullivan AJ & Ho KK. Route-dependent endocrine and metabolic effects of estrogen replacement therapy. Journal of Pediatric Endocrinology and Metabolism 2000 13 (Suppl 6) 1457-1466.
49. Helle SI, Omsjo IH, Hughes SC, Botta L, Huls G, Holly JM et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clinical Endocrinology 1996 45 727-732.
50. Raudaskoski T, Knip M & Laatikainen T. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy. Menopause 1998 5 217-222.
51. Helle SI, Anker GB, Meadows KA, Holly JM & Lonning PE. Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. Maturitas 1998 28 259-265.
52. Massa G, Igout A, Rombauts L, Frankenne F & Vanderschueren-Lodeweyckx M. Effect of oestrogen status on serum levels of growth hormone-binding protein and insulin-like growth factor-I in non-pregnant and pregnant women. Clinical Endocrinology 1993 39 569-575.
53. De Pergola G, Cospite MR, Giagulli VA, Giorgino F, Garruti G, Cignarelli M et al. Insulin-like growth factor-1 (IGF-1) and dehydroepiandrosterone sulphate in obese women. International Journal of Obesity Related Metabolic Disorders 1993 17 481-483.
54. Hojbjerg GC, Svenstrup B, Bennett P & Sandahl CJ. Reduced androgen levels in adult turner syndrome: influence of female sex steroids and growth hormone status. Clinical Endocrinology 1999 50 791-800.
55. Maccario M, Ramunni J, Oleandri SE, Procopio M, Grottoli S, Rossetto R et al. Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. International Journal Obesity Related Metabolic Disorders 1999 23 612-618.
56. Thierry van Dessel HJ, Chandrasekher Y, Yap OW, Lee PD, Hintz RL, Faessen GH et al. Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle. Journal of Clinical Endocrinology and Metabolism 1996 81 1224-1231.
57. Blake EJ, Adel T & Santoro N. Relationships between insulin-like growth hormone factor-I and estradiol in reproductive aging. Fertility and Sterility 1997 67 697-701.
58. Juul A, Scheike T, Pedersen AT, Main KM, Andersson AM, Pedersen LM et al. Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Human Reproduction 1997 12 2123-2128.
59. Klinger B, Anin S, Silbergeld A, Eshet R & Laron Z. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clinical Endocrinology 1998 48 81-87.
60. Laron Z & Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). European Journal of Endocrinology 1998 138 176-180.
61. Cara JF & Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988 123 733-739.
62. Hernandez ER, Resnick CE, Svoboda ME, Van-Wyk JJ, Payne DW & Adashi EY. Somatomedin-C/insulin-like growth factor I as an enhancer of androgen biosynthesis by cultured rat ovarian cells. Endocrinology 1988 122 1603-1612.
63. Mesiano S, Katz SL, Lee JY & Jaffe RB. Insulin-like growth factors augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: implications for adrenal androgen regulation. Journal of Clinical Endocrinology and Metabolism 1997 82 1390-1396.
64. Penhoat A, Chatelain PG, Jaillard C & Saez JM. Characterization of insulin-like growth factor I and insulin receptors on cultured bovine adrenal fasciculata cells Role of these peptides on adrenal cell function. Endocrinology 1988 122 2518-2526.
65. Kanematsu T, Irahara M, Miyake T, Shitsukawa K & Aono T. Effect of insulin-like growth factor I on gonadotropin release from the hypothalamus-pituitary axis in vitro. Acta Endocrinologica 1991 125 227-233.
66. Chandrashekar V & Bartke A. Induction of endogenous insulin-like growth factor-I secretion alters the hypothalamic-pituitary-testicular function in growth hormone-deficient adult dwarf mice. Biology of Reproduction 1993 48 544-551.
67. Singh A, Hamilton-Fairley D, Koistinen R, Seppala M, James VH, Franks S et al. Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. Journal of Endocrinology 1990 124 R1-R3.
68. Kalme T, Koistinen H, Loukovaara M, Koistinen R & Leinonen P. Comparative studies on the regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) and sex hormone-binding globulin (SHBG) production by insulin and insulin-like growth factors in human hepatoma cells. Journal of Steroid Biochemistry and Molecular Biology 2003 86 197-200.